See more : Magazine Luiza S.A. (MGLUY) Income Statement Analysis – Financial Results
Complete financial analysis of Astellas Pharma Inc. (ALPMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Astellas Pharma Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Ping An Insurance (Group) Company of China, Ltd. (601318.SS) Income Statement Analysis – Financial Results
- QuantumKore Inc. (SBOX) Income Statement Analysis – Financial Results
- Moong Pattana International Public Company Limited (MOONG.BK) Income Statement Analysis – Financial Results
- Quantafuel ASA (QFUEL.OL) Income Statement Analysis – Financial Results
- Valmont Industries, Inc. (VMI) Income Statement Analysis – Financial Results
Astellas Pharma Inc. (ALPMY)
About Astellas Pharma Inc.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,603.67B | 1,518.62B | 1,296.16B | 1,249.53B | 1,300.84B | 1,306.35B | 1,300.32B | 1,311.67B | 1,372.71B | 1,247.26B | 1,139.91B | 1,005.61B |
| Cost of Revenue | 292.49B | 326.79B | 281.29B | 269.83B | 297.90B | 327.26B | 330.09B | 356.34B | 377.98B | 333.20B | 330.63B | 324.13B |
| Gross Profit | 1,311.19B | 1,191.83B | 1,014.87B | 979.70B | 1,002.94B | 979.09B | 970.23B | 955.33B | 994.72B | 914.06B | 809.28B | 681.49B |
| Gross Profit Ratio | 81.76% | 78.48% | 78.30% | 78.41% | 77.10% | 74.95% | 74.61% | 72.83% | 72.46% | 73.29% | 71.00% | 67.77% |
| Research & Development | 294.20B | 276.13B | 246.01B | 224.49B | 224.23B | 208.68B | 220.78B | 208.13B | 225.67B | 206.60B | 191.50B | 181.96B |
| General & Administrative | 740.11B | 630.27B | 548.84B | 504.32B | 499.30B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 259.16B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.50B |
| SG&A | 740.11B | 630.27B | 548.84B | 504.32B | 499.30B | 490.26B | 478.21B | 470.78B | 498.48B | 452.52B | 397.02B | 345.66B |
| Other Expenses | 251.36B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1,285.67B | 906.40B | 794.85B | 728.81B | 723.52B | 698.95B | 698.99B | 678.91B | 724.15B | 726.32B | 688.90B | 558.62B |
| Cost & Expenses | 1,578.15B | 1,233.19B | 1,076.14B | 998.63B | 1,021.42B | 1,026.21B | 1,029.08B | 1,035.25B | 1,102.13B | 1,059.52B | 1,019.53B | 882.75B |
| Interest Income | 11.46B | 5.21B | 794.00M | 683.00M | 2.16B | 2.69B | 1.65B | 978.00M | 985.00M | 1.94B | 1.59B | 1.81B |
| Interest Expense | 12.01B | 3.62B | 4.95B | 2.34B | 3.00B | 1.30B | 1.31B | 1.33B | 1.26B | 3.08B | 1.66B | 1.82B |
| Depreciation & Amortization | 157.84B | 105.74B | 79.68B | 72.65B | 66.40B | 63.46B | 64.86B | 63.79B | 69.19B | 65.47B | 64.30B | 57.86B |
| EBITDA | 194.81B | 246.88B | 241.52B | 220.31B | 314.75B | 313.73B | 284.76B | 347.54B | 332.59B | 258.24B | 187.94B | 180.10B |
| EBITDA Ratio | 12.15% | 25.76% | 23.12% | 25.89% | 26.58% | 26.30% | 25.85% | 25.94% | 24.75% | 23.44% | 21.70% | 21.05% |
| Operating Income | 25.52B | 285.43B | 220.02B | 250.90B | 279.42B | 280.14B | 271.24B | 276.42B | 270.58B | 226.87B | 183.09B | 153.87B |
| Operating Income Ratio | 1.59% | 18.80% | 16.97% | 20.08% | 21.48% | 21.44% | 20.86% | 21.07% | 19.71% | 18.19% | 16.06% | 15.30% |
| Total Other Income/Expenses | -549.00M | -668.00M | 711.00M | 8.80B | 3.02B | 5.06B | 4.86B | 5.35B | -8.81B | -37.19B | 5.17B | 3.08B |
| Income Before Tax | 24.97B | 131.10B | 156.40B | 144.85B | 247.01B | 248.97B | 218.11B | 281.77B | 261.77B | 189.68B | 121.97B | 124.67B |
| Income Before Tax Ratio | 1.56% | 8.63% | 12.07% | 11.59% | 18.99% | 19.06% | 16.77% | 21.48% | 19.07% | 15.21% | 10.70% | 12.40% |
| Income Tax Expense | 7.92B | 33.65B | 32.80B | 24.73B | 49.94B | 26.70B | 53.43B | 63.07B | 68.08B | 53.83B | 31.10B | 41.82B |
| Net Income | 17.05B | 98.71B | 124.09B | 120.59B | 195.41B | 222.27B | 164.68B | 218.70B | 193.69B | 135.86B | 90.87B | 82.85B |
| Net Income Ratio | 1.06% | 6.50% | 9.57% | 9.65% | 15.02% | 17.01% | 12.66% | 16.67% | 14.11% | 10.89% | 7.97% | 8.24% |
| EPS | 9.47 | 54.24 | 67.08 | 64.93 | 104.15 | 115.05 | 81.11 | 103.69 | 89.75 | 61.40 | 40.39 | 36.03 |
| EPS Diluted | 9.47 | 54.09 | 67.05 | 64.90 | 104.08 | 114.94 | 81.02 | 103.55 | 89.62 | 61.40 | 40.39 | 36.03 |
| Weighted Avg Shares Out | 1.80B | 1.82B | 1.85B | 1.86B | 1.88B | 1.93B | 2.03B | 2.11B | 2.16B | 2.21B | 2.25B | 2.30B |
| Weighted Avg Shares Out (Dil) | 1.80B | 1.83B | 1.85B | 1.86B | 1.88B | 1.93B | 2.03B | 2.11B | 2.16B | 2.21B | 2.25B | 2.30B |
Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
Japan's Astellas says employee indicted by China's prosecutors
UK regulator approves Astellas' gastric cancer drug
Astellas Pharma Inc. (ALPMF) Q1 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports